Subacute cutaneous lupus erythematosus with positive anti-Ro antibodies following palbociclib and letrozole treatment: A case report and literature review.
Eleanor Russell-GoldmanRosalynn M NazarianPublished in: Journal of cutaneous pathology (2020)
Drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) is an uncommon but well-described phenomenon, most often seen in association with antihypertensives and antifungal medications. In recent years, rare reports of DI-SCLE have been described in patients being treated with targeted therapies. Herein, we describe a case of DI-SCLE in association with palbociclib and letrozole treatment for metastatic breast cancer. This report is the first known case of DI-SCLE with positive anti-Ro antibodies in this setting. We also summarize the literature describing DI-SCLE in association with targeted therapies to date and its possible association with dysregulation of the vascular endothelial growth factor pathway.
Keyphrases
- metastatic breast cancer
- drug induced
- vascular endothelial growth factor
- systemic lupus erythematosus
- liver injury
- systematic review
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- metabolic syndrome
- disease activity
- adipose tissue
- rheumatoid arthritis
- candida albicans
- staphylococcus aureus
- early breast cancer
- patient reported